CLAIMS

WHAT IS CLAIMED IS:

1. An isolated polypeptide comprising a modified sequence that comprises SEQ ID NO:2, wherein the modified sequence is non-sialylated and the polypeptide has an anti-inflammatory activity that is higher than that of a parent sialylated polypeptide that comprises SEQ ID NO:1; and wherein the isolated polypeptide has an ability to bind to DC-SIGN, hFcγRIIA, and RIIB.

2. The isolated polypeptide of claim 1, wherein the isolated polypeptide has an ability to bind to hFcγRIIA or RIIB at a K_D of $2x10^{-5}$ M or lower (i.e., K_A of 5.0×10^4 M^{-1} or higher).

3. The isolated polypeptide of claim 1 or 2, wherein the modified sequence consists of SEQ ID NO: 2.

4. An isolated nucleic acid comprising a sequence encoding the polypeptide of any of claims 1-3.

5. An expression vector or a host cell comprising a nucleic acid of claim 4.

6. A method of producing a polypeptide, comprising culturing the host cell of claim 5 in a medium under conditions permitting expression of a polypeptide encoded by the nucleic acid, and purifying the polypeptide from the cultured cell or the medium of the cell.

7. A pharmaceutical formulation comprising (i) the polypeptide of any of claims 1-3 or a nucleic acid of claim 4, and (ii) a pharmaceutically acceptable carrier.

8. A polypeptide of any of claims 1-3 or a nucleic acid of claim 4 for use in treating an inflammatory disease.